Aziz Kabeer's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Sep 29, 2023
- Accession no.
- 0000950170-23-050851
- Filed
- Sep 29, 2023
- Trade date
- Sep 27-28, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $150.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aziz KabeerCIK 0001914847 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2023 | Common Stock | SSaleDisposed | −707 | $16.07 | −$11,361.49 | 2,176,840 | Indirect | |
| Sep 27, 2023 | Common Stock | SSaleDisposed | −134 | $16.07 | −$2,153.38 | 411,759 | Indirect | |
| Sep 28, 2023 | Common Stock | SSaleDisposed | −7,160 | $16.11 | −$115,347.6 | 2,169,680 | Indirect | |
| Sep 28, 2023 | Common Stock | SSaleDisposed | −1,356 | $16.11 | −$21,845.16 | 410,403 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.